Invesaro

Stocks Real estate CVSA

NYSE · Real estate

Covista Inc. (CVSA)

Covista Inc. reported revenue of $2B in fiscal 2026, up 9.3% from a year earlier. Net income was $251.6M, a net margin of 12.9%. Operating cash flow minus capital spending left $392.7M of free cash flow in fiscal 2026. At June 30, 2026 it held $406.3M in cash against $662.9M of debt. Its latest periodic report to the SEC is the annual report (10-K) filed on August 6, 2026.

Price
$120.75
-2.75% on the day · September 25, 2026
52-week range $86.97 to $156.26
Market cap
$4.1B
Revenue (FY2026)
$2B
+9.3% year on year
Net margin
12.9%
P/E
17.2
on FY2026 diluted EPS

What Covista Inc. does

Covista Inc. is registered with the SEC under industry code SIC 8200 (Services-Educational Services). Its shares trade on NYSE under the ticker CVSA.

Revenue and profit by year

Revenue
FY19: $1B $1B FY19FY20: $866.4M $866.4M FY20FY21: $899.2M $899.2M FY21FY22: $1.4B $1.4B FY22FY23: $1.5B $1.5B FY23FY24: $1.6B $1.6B FY24FY25: $1.8B $1.8B FY25FY26: $2B $2B FY26
Net income
FY19: $95.2M $95.2M FY19FY20: -$85.3M -$85.3M FY20FY21: $70M $70M FY21FY22: $311M $311M FY22FY23: $93.4M $93.4M FY23FY24: $136.8M $136.8M FY24FY25: $237.1M $237.1M FY25FY26: $251.6M $251.6M FY26

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2026$2B$383.4M$251.6M$7.04$392.7M
2025$1.8B$341.5M$237.1M$6.18$287.6M
2024$1.6B$217.1M$136.8M$3.39$246.9M
2023$1.5B$168.2M$93.4M$2.05$165.9M
2022$1.4B$76.7M$311M$6.43-$20.5M
2021$899.2M$110.4M$70M$1.36$152.3M

Latest SEC filings

What Covista Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. September 23, 2026
    Material agreement 8-K
  2. September 8, 2026
    Passive stake changed SCHEDULE 13G/A
  3. August 6, 2026
    Annual report 10-K · period to June 30, 2026
  4. August 6, 2026
    Quarterly results 8-K
  5. August 6, 2026
    Passive stake changed SCHEDULE 13G/A
  6. July 28, 2026
    Executive or director change 8-K
  7. June 1, 2026
    Employee plan annual report 11-K
  8. May 7, 2026
    Quarterly report 10-Q · period to March 31, 2026
  9. May 7, 2026
    Quarterly results 8-K
  10. May 6, 2026
    Passive stake (5% or more) SCHEDULE 13G

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 1, 2026. Insider transactions on SEC

All filings on SEC EDGAR

Questions about CVSA

What does Covista Inc. do?

Covista Inc. is registered with the SEC under industry code SIC 8200 (Services-Educational Services). Its shares trade on NYSE under the ticker CVSA.

Is Covista Inc. profitable?

Yes. In fiscal 2026 it reported net income of $251.6M on revenue of $2B, a net margin of 12.9%.

How much revenue does Covista Inc. make?

In fiscal 2026 Covista Inc. reported revenue of $2B. That is 9.3% more than a year earlier.

When did Covista Inc. last report?

Its most recent periodic report is the annual report (10-K) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the material agreement from September 23, 2026.

Similar companies

GHC
Graham Holdings Co
AFYA
Afya Ltd
TAL
TAL Education Group
LRN
Stride, Inc.
LAUR
Laureate Education, Inc.
STRA
Strategic Education, Inc.

Follow CVSA

Get an email when Covista Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow CVSA: get an email when it files

Where the numbers come from

Financial figures are the values Covista Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.